Press Releases

Antigenics Reports Second Quarter 2010 Financial Results
July 29, 2010

Antigenics Presents Positive, Top Line Data from Phase I Herpes Clinical Trial
July 27, 2010

Antigenics to Report Second Quarter Financial Results on July 29, 2010; Conference Call to Follow
July 22, 2010

Antigenics Receives NASDAQ Delisting Notification
July 21, 2010

Encouraging Data Presented on Oncophage® Vaccine at International Conference on Brain Tumor Research and Therapy
May 20, 2010

Antigenics Reports First Quarter 2010 Financial Results
April 29, 2010

Antigenics to Webcast 2010 Annual Shareholders Meeting
April 29, 2010

Antigenics to Report First Quarter Financial Results on April 29, 2010; Conference Call to Follow
April 29, 2010

Antigenics Reports Fourth Quarter and Year-End 2009 Financial Results
February 18, 2010

Antigenics to Report Fourth Quarter and Year-End 2009 Financial Results on February 18, 2010; Conference Call to Follow
February 11, 2010

Antigenics Receives NASDAQ Delisting Notification
December 31, 2009

European CHMP Formally Adopts Negative Opinion on Oncophage®
November 20, 2009

Antigenics Provides Details On GlaxoSmithKline’s Pivotal Malaria Vaccine Trial With QS-21 Adjuvant
November 4, 2009

Antigenics Reports Third Quarter 2009 Financial Results
October 29, 2009

Data Presented On Oncophage Cancer Vaccine In Recurrent Glioma At SNO 2009
October 26, 2009

Antigenics to Report Third Quarter 2009 Financial Results on October 29, 2009; Conference Call to Follow
October 22, 2009

Antigenics Announces a Negative Vote From the CHMP on Oncophage® Marketing Application in Europe
October 21, 2009

Antigenics Announces Expansion of its QS-21 License Agreement
September 21, 2009

Patients Begin Enrolling into Investigator-Sponsored Phase 2 Trial of Antigenics’ Oncophage® Cancer Vaccine in Newly Diagnosed Glioma
August 12, 2009

Antigenics to Raise $10 Million in Private Placement
August 4, 2009

Antigenics Reports Second Quarter 2009 Financial Results
July 30, 2009